Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
In this pilot and feasibility study, the investigators will enroll patients with frequent
symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different
classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide
preliminary data for a larger study in which the investigators will test the hypothesis that
a common AF genetic risk allele modulates response to different AADs.
Phase:
Phase 4
Details
Lead Sponsor:
University of Illinois at Chicago Vanderbilt University